Biomarkers in Hepatocellular Carcinoma: Diagnosis, Prognosis and Treatment Response Assessment
Top Cited Papers
Open Access
- 31 May 2020
- Vol. 9 (6), 1370
- https://doi.org/10.3390/cells9061370
Abstract
Hepatocellular carcinoma (HCC) is one of the main cancer-related causes of death worldwide. Thus, there is a constant search for improvement in screening, diagnosis, and treatment strategies to improve the prognosis of this malignancy. The identification of useful biomarkers for surveillance and early HCC diagnosis is still deficient, with available serum biomarkers showing low sensitivity and heterogeneous specificity despite different cut-off points, even when assessed longitudinally, or with a combination of serum biomarkers. In contrast, HCC biomarkers used for prognostic (when associated with clinical outcomes) or predictive purposes (when associated with treatment response) may have an increased clinical role in the near future. Furthermore, some serum biomarkers are already implicated as a treatment selection tool, whether to provide access to certain therapies or to assess clinical benefit after treatment. In the present review we will discuss the clinical utility and foreseen future of HCC biomarkers implicated in surveillance, diagnosis, prognosis, and post-treatment assessment.This publication has 189 references indexed in Scilit:
- Prolyl-4-hydroxylase α subunit 2 promotes breast cancer progression and metastasis by regulating collagen depositionBMC Cancer, 2014
- Prognostic value of α-fetoprotein and des-γ-carboxy prothrombin responses in patients with hepatocellular carcinoma treated with transarterial chemoembolizationBMC Cancer, 2013
- The Use and Interpretation of Competing Risks Regression ModelsClinical Cancer Research, 2012
- Combining Clinical, Pathology, and Gene Expression Data to Predict Recurrence of Hepatocellular CarcinomaGastroenterology, 2011
- Response to Therapy as a Criterion for Awarding Priority to Patients With Hepatocellular Carcinoma Awaiting Liver TransplantationAnnals of Surgical Oncology, 2010
- α-Fetoprotein, Des-γ Carboxyprothrombin, and Lectin-Bound α-Fetoprotein in Early Hepatocellular CarcinomaGastroenterology, 2009
- Sorafenib in Advanced Hepatocellular CarcinomaThe New England Journal of Medicine, 2008
- Diagnostic accuracy of tumor markers for hepatocellular carcinoma: a systematic reviewHepatology International, 2007
- The Utility of Lens Culinaris Agglutinin-Reactive α-Fetoprotein in the Diagnosis of Hepatocellular Carcinoma: Evaluation in a United States Referral PopulationClinical Gastroenterology and Hepatology, 2007
- Randomized controlled trial of screening for hepatocellular carcinomaZeitschrift für Krebsforschung und Klinische Onkologie, 2004